Mr. Donald Todd serves as President, Asia Pacific of STAAR Surgical Company. Mr. Todd joined STAAR on August 16, 2010. From 2008 to 2010 he served as Global Vice President for VNUS Medical Technologies, a division of Covidien Company, specializing in Radio Frequency treatment for venous insufficiency. Prior to that position, he worked for three years from 2005 to 2008 as Senior Vice President, Marketing for Iridex Corporationration, an ophthalmic and aesthetic laser company. His background includes Executive Vice President and senior management positions in cardiovascular and ophthalmic medical device companies such as CooperVision/Alcon, Iolab, Sorin Group, Venetec International and Terumo Medical
President Asia Pacific
|Todd earned a Bachelor of Arts degree in Business Administration from Colorado State University.|
The company has return on total asset (ROA) of 1.71 % which means that it generated profit of $1.71 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (5.76) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 7.17 M in liabilities with Debt to Equity (D/E) ratio of 0.23 which may suggest the company is not taking enough advantage from borrowing. STAAR Surgical Company has Current Ratio of 2.41 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.
Entity SummarySTAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures and sells implantable lenses for the eye. STAAR Surgical Company [STAA] is traded on NASDAQ General Markets in USA. It is located in Monrovia, CA and employs 301 people. Filter other
|Click to run this filter|| |
Filter Other Insiders
| STAA Nasdaq
STAAR Surgical Company
STAAR Surgical Company has less than 1.0 (%) percent chance of experiencing financial distress in the next 2 years of operations.
STAAR price boundaries
Promote STAAR and Donald Todd